key: cord-1050214-0t2m4mfo authors: Graham, Jessica; Hillegass, Jedd; Schulze, Gene title: Considerations for setting occupational exposure limits for novel pharmaceutical modalities date: 2020-11-02 journal: Regul Toxicol Pharmacol DOI: 10.1016/j.yrtph.2020.104813 sha: c343a7fd4a381d2c2d883115737d60b68b4880ad doc_id: 1050214 cord_uid: 0t2m4mfo In order to develop new and effective medicines, pharmaceutical companies must be modality agnostic. As science reveals an enhanced understanding of biological processes, new therapeutic modalities are becoming important in developing breakthrough therapies to treat both rare and common diseases. As these new modalities progress, concern and uncertainty arise regarding their safe handling by the researchers developing them, employees manufacturing them and nurses administering them. This manuscript reviews the available literature for emerging modalities (including oligonucleotides, monoclonal antibodies, fusion proteins and bispecific antibodies, antibody-drug conjugates, peptides, vaccines, genetically modified organisms, and several others) and provides considerations for occupational health and safety-oriented hazard identification and risk assessments to enable timely, consistent and well-informed hazard identification, hazard communication and risk-management decisions. This manuscript also points out instances where historical exposure control banding systems may not be applicable (e.g. oncolytic viruses, biologics) and where other occupational exposure limit systems are more applicable (e.g. Biosafety Levels, Biologic Control Categories). premise of the ECB classification system is to place chemicals into categories based on their 225 inherent toxicity and potency, which offers a simplified solution for controlling worker exposures 226 to compounds in the workplace. Briefly, an initial hazard assessment is conducted in an effort 227 to identify potential exposure ranges expected to represent negligible risk for the physical (e.g. 228 corrosivity), toxicological, and/or pharmacological effect(s) of concern. The mechanism of 229 pharmacological action, in vitro / in vivo potency, preclinical dose-response related effects, 230 bioavailability (inhalation, oral and dermal), therapeutic dose, and the spectrum and severity of 231 clinically observed adverse effects of a specific drug substance, all provide the basis for the 232 hazard assessment. Preclinical data such as QSAR (in silico predictive systems) and animal 233 data is also considered in the hazard assessment, and one or more compound characteristics 234 may be responsible for placing a compound in a specific ECB. It is generally prudent to assign 235 compounds to more protective bands earlier in their development, and as new data emerges, 236 subsequently adjust their occupational exposure limits/bands to less restrictive bands and 237 corresponding handling practices (with the goal being to ensure workers in the early 238 development space are adequately protected). 239 The banding system is integrated into the organization's engineering controls and thus 240 may be different across organizations. For illustrative purposes, Table 1 presents a typical 241 pharmaceutical compound banding system and is the one employed by Bristol Myers Squibb 242 (BMS). The cutoffs for the bands/categories presented are based on several factors, including 243 approaches based on the threshold of toxicological concern (TTC) [5] [6] [7] [8] [9] [10] . While the TTC may 244 not be originally derived for occupational purposes, the principles have been applied 245 successfully in the field of occupational health and safety for the establishment of safe 246 occupational exposure limits [11] [12] [13] [14] . TTC limits can be applied using an assumed breathing 247 volume of 10 m 3 and 100% inhalation bioavailability. The banding recommendations included in 248 this manuscript for compounds including small molecules, antibody drug conjugates, 249 oligonucleotides and biologic material made through chemical synthesis, are based on those 250 J o u r n a l P r e -p r o o f presented in Table 1 . For more information on occupational exposure banding systems and 251 applications including suggested exposure controls and handling practices see the following 252 references [3-5, 15, 16] . 253 254 Highly toxic / potent compounds A TTC of 10 µg/day b is recommended for relatively unstudied compounds that may be highly potent or highly toxic with limited data to indicate they may produce pharmacologic or toxic effects at very low doses [6] [7] [8] . Toxic oncology drugs, potent compounds, chemically synthesized peptides, antibody drug conjugates, steroids 5 special case < 0.1 Especially potent / toxic compounds A TTC of 1 µg/day b is recommended in the absence of sufficient data for anti-cancer drugs, which are developmental toxicants, mutagenic, or may be Especially potent/toxic compounds, protein nucleic acids J o u r n a l P r e -p r o o f carcinogenic [6, 17, 18 ]. a The banding recommendations presented reflect the assumption that an employee will inhale 256 10 m 3 of air daily during his/her 8-hour shift [19] . 257 b A threshold of 1.5 µg/day is recommended for relatively unstudied compounds which may be 258 mutagenic or carcinogenic [10] . 259 260 261 Due to the general instability of biologic therapeutics, differences in their manufacturing 263 (generally closed processes to protect sterility) and their potential limited bioavailability (BA) via 264 the inhalation, oral and dermal routes [20] [21] [22] [23] , it can be argued that a different set of exposure 265 controls can be utilized to protect employees when working with biologics as compared to small 266 molecules. Based on this information as well as extensive industrial hygiene monitoring 267 conducted by BMS showing that airborne concentrations of biologics are most often <1 µg/m 3 268 (data not shown), a simplified two-band system was developed for biologics for use when there 269 is insufficient information available to calculate an OEL. Therefore, a two-category system for 270 banding mid-to high-molecular weight (MW) biologics made through biological processes (i.e., 271 mammalian cell culture) is implemented at BMS and is presented in Table 2 . Essentially, active 272 biologic materials that are made through biological processing (i.e. cell culture), can be 273 categorized into one of two Biologic Control Categories (BCC) (BCC A or BCC B). BCC A or 274 BCC B is assigned based on the hazards and potency of the biologic of concern (See Figure 1). 275 For potent or toxic therapeutic proteins or other biologic compounds, BCC B exposure controls 276 (and corresponding handling practices) should be utilized. Note that while Table 2 illustrates 277 banding system that BMS implements for biologics, alternative schemes are also utilized in the 278 pharmaceutical industry which are equally effective in controlling exposures. Additionally, for 279 compounds expected to pose special hazards, a compound-specific risk assessment can be 280 completed to confirm whether additional exposure controls are needed (e.g. BCC B controls 281 with additional personal protective equipment). Also, note that once a sufficient data package is 282 J o u r n a l P r e -p r o o f available to establish an OEL (also referred to as a health-based exposure limit [HBEL] In order to assist in the selection of the appropriate ECB or BCC for pharmaceutical modalities 291 discussed in subsequent sections, a decision tree was generated as shown in Figure 1 . The 292 primary consideration for band selection is pharmacological potency in vivo, and details 293 regarding derivation of the pharmacological potency levels which can differentiate between 294 bands, bioavailability considerations, and additional toxicities which may warrant an additional 295 safety factor are described in more detail within this article (see Sections 3.1.7 and 3.4.7). This 296 decision tree focuses specifically on ECB 4, 5, and 5sc (for small molecules) since early in drug 297 development when the banding approach is most applicable, limited data are available such that 298 less restrictive bands would not be considered, and active pharmaceutical ingredients (APIs) 299 would generally default to one of these three bands. It should be noted that this decision tree, 300 and the doses included therein, should be considered as a rough guide for initial band selection. 301 Ultimate selection of the band should come from a qualified occupational toxicologist, and rely 302 on the consideration of a number of additional criteria as described in this article, including the 303 J o u r n a l P r e -p r o o f Small molecules exert pharmacologic effects through various mechanisms of action, including 318 but not limited to: 1) agonism / antagonism of specific receptors (e.g. tamoxifen), 2) enzyme 319 inhibition (e.g. apixaban), 3) hormonal interaction (e.g. levonorgestrel), 4) alkylation (e.g. 320 lomustine), and 5) inhibition of transporters (e.g. dapagliflozin). Their small size allows for the 321 possibility of rapid diffusion across cell membranes so that they can reach intracellular sites of 322 action [24, 25] . 323 Approximately 20% of all small molecule drugs approved during the period of 2000 to 324 2008 were prodrugs [26] and they remain a significant portion of drugs being developed [27] . 325 Prodrugs are inactive derivatives of active drug molecules that must undergo an enzymatic 326 and/or chemical transformation in vivo to release/become the active drug, which can then elicit 327 its desired pharmacological effect in the body [26] . 328 329 J o u r n a l P r e -p r o o f Small molecules make up the majority of marketed pharmaceuticals. Examples of small 331 molecule pharmaceutical drugs include many cardiovascular drugs (e.g. Eliquis® or Apixaban), 332 antivirals (e.g. Daclatasvir or Daklinza®), and diabetes therapeutics (e.g. Farxiga® or 333 Dapagliflozin), to name a few. One example of a prodrug is Vyvanse® (a form of amphetamine 334 used to treat attention-deficit / hyperactivity disorder) which is designed to have less abuse 335 potential than other amphetamines due to the slower release of the active drug following 336 bioconversion in the intestine/liver. Another example of a prodrug is omeprazole (a proton 337 pump inhibitor used to treat acid reflux and ulcers) which is bioactivated site-selectively in the 338 acidic conditions of the stomach. 339 340 The absorption of a small molecule drug is highly variable and dependent on multiple factors 342 including its hydrophobicity/hydrophilicity, size, molecular charge / ionization state, and 343 plasma/protein binding potential. Small molecule drugs are generally administered orally and 344 are designed to have high oral BA, which can give them an ease of use advantage over high 345 MW drugs that require parenteral administration. Small molecule pharmaceuticals are designed 346 to be stable alone and/or in formulation enabling a long shelf-life and the ability to reach cellular 347 targets intact with consistent pharmacological potency [28] . In most cases, prodrugs are simple 348 chemical derivatives that are only one or two chemical or enzymatic steps away from the active 349 parent drug. Prodrugs are typically designed to improve the pharmacokinetic (PK) profile of the 350 active drug and can also facilitate the intracellular localization of drugs. The liver is generally 351 assumed to be the major site of first-pass metabolism of a small molecule drug administered 352 There are many different routes of excretion including via the urine, bile, sweat, saliva, 354 tears, milk, and stool. The majority of drugs are eliminated via pathways that involve the 355 kidneys and/or the liver. A major characteristic of compounds excreted in urine is that they are 356 polarized (i.e., charged) and water-soluble. Drugs that are lipid soluble are not readily removed 357 by the kidneys and require hepatic metabolism (e.g. phase I and phase II biotransformation 358 reactions) to increase their water solubility for possible urinary excretion [29] . Drugs with a MW 359 exceeding 300 Da and with polar and lipophilic groups are more likely to be excreted in bile [30] . 360 361 3.1.5. Health hazards associated with therapeutic use 362 Due to their small size, the oral and inhalation BA of small molecules is often quite high (>50%). 363 In general, the hazards associated with small molecule drugs are due to their pharmacological 364 effects or exaggerated pharmacology. Hazards can also be due to off-target effects. 365 In general, the hazards of prodrugs are the same as for small molecules. Prodrugs can 366 be metabolized into more active or less active forms, which can contribute to their 367 pharmacology and/or toxicity. Small molecules can elicit effects via the oral, dermal, inhalation and systemic routes (in 371 addition to others) therefore exposure via each of these occupational exposure routes is of 372 concern. Regarding inhalation exposure, it is important to consider the molecule's potential to 373 exert direct effects on the lung (e.g. target receptor present in the lung, pulmonary vasodilator) 374 as well as the compound's systemic BA via the inhalation route. In the absence of inhalation BA 375 data, it is acceptable to conservatively assume 100% of the inhaled dose reaches the systemic 376 circulation. There is also the potential for dermal absorption for this class of compounds and 377 therefore the potential for dermal toxicity due to dermal absorption and subsequent systemic 378 exposure. 379 When assigning a small molecule to an ECB (Figure 1 ), the goal is to ensure that employees 382 are adequately protected throughout their tenure working with the compound of concern. Since 383 the data to support the calculation of the OEL is not available in the early development space, 384 assumptions need to be made to enable the determination of the appropriate ECB. These 385 assumptions include information and confidence in the dose where biologically significant (and 386 clinically relevant) pharmacology is expected. Adhering to the suggested doses where 387 biologically significant pharmacology is observed in Figure 1 provides a 100-fold safety factor 388 from the midpoint of the band for a 50 kg individual (bodyweight recommended when 389 establishing permissible daily exposure limits) [31] . It is important to note that cytotoxic 390 compounds, mutagens, teratogens and hormones may require a greater safety factor due to 391 their potential for severely toxic effects. It is BMS's practice that the default band for 392 pharmacologically-active, small molecule APIs can be considered to be ECB 4, however this 393 default band should be reconsidered if a molecule is expected to be extremely potent/toxic or 394 based on professional judgment. 395 Another helpful piece of information when establishing the ECB is the projected (or actual) 397 lowest human therapeutic dose. Compounds which may have a therapeutic dose of <1 mg/day 398 may need to be placed into ECB 5 or 5 special case in order to allow for an acceptable margin 399 of safety, in this instance defined as the exposure margin between the therapeutic dose and the 400 midpoint of the occupational exposure band. Information on the PK of the compound such as 401 half-life and oral BA, along with pharmacodynamics (PD), should also be considered if available. 402 For example, a compound with a long half-life (on the order of days) may bioaccumulate, 403 resulting in a lower acceptable occupational exposure than for a compound with a half-life of 404 hours. For compounds that are prodrugs, the ECB should be consistent with that of the more 405 active form, taking into account the rate of formation of the active and the route of exposure. Peptides are cleared by the same catabolic pathways used to eliminate endogenous and dietary 535 proteins, and are generally regarded as having a predictable metabolism [41] . They also tend to 536 be chemically and physically unstable in the general environment, are prone to hydrolysis and 537 oxidation, have a tendency for aggregation, exhibit a relatively short circulating plasma half-life 538 and fast elimination, and have low membrane permeability [40] . Several drug delivery 539 strategies employ binding the peptide of interest to the circulating protein albumin as a means of 540 obtaining an extended half-life, leading to less frequent dosing, in some cases only once weekly 541 [40]. 542 543 Inhalation of therapeutic peptides has been examined in the clinic and in preclinical studies; 545 however, in these studies the therapeutic target(s) was present in the lung [42] [43] [44] [45] [46] . Inhalation 546 studies with peptides have shown that they have the potential to produce local immunogenicity 547 and irritation upon chronic exposure [43] . Given that therapeutic doses generally need to be 548 administered with a delivery device to ensure sufficient lung exposure, occupationally relevant 549 airborne exposures to therapeutic peptides are expected to be lower than the levels which 550 would cause adverse effects in the lung. The potential for direct lung effects (resulting from the 551 therapeutic target being present in the lung), however, would need to be considered. For 552 peptides where there is no target in the lung, the inhalation route would be less of a concern, 553 although inhalation BA would still need to be considered. An evaluation of inhalation studies Peptides are generally unstable in the environment (e.g. degrade upon prolonged exposure to 559 light, temperature-sensitive), therefore any pharmacological activity may be lost over time 560 J o u r n a l P r e -p r o o f should the material be present on a work surface [23] . Although there are a few marketed oral 561 peptides, in general peptides are not orally bioavailable due to their instability in the GI tract 562 [40]. Dermal exposure would also be of limited concern due to the size of these compounds, 563 the fact that they are naturally occurring proteins and their relative instability under 564 environmental conditions. Exposure via inhalation is a concern, especially when there are 565 potential targets present in the lung (e.g. compounds that target glucocorticoid receptors). 566 Additionally, enzyme proteins have been reported to cause occupational allergies such as 567 asthma [47] . Needle sticks and sharps exposures are also a concern as there is a potential for 568 immunogenicity upon systemic exposure [40] . 569 570 Based on the chemical synthesis used, small size and higher BA of these compounds 572 compared with large MW biologics, peptides can be banded according to the small-molecule 573 ECB system (See Figure 1 ). Even if made via a biologic process, their small size precludes 574 them from the BCC system. Similar to small molecules, peptides can be placed in ECB-4 as a 575 Cancer immunotherapies have been established as a highly effective therapeutic option. 666 Ipilimumab was a first-in-class T-cell potentiator that works by blocking cytotoxic T-lymphocyte 667 antigen-4 (CTLA-4), a critical protein receptor that downregulates the immune system [60] . 668 Other approved mAbs include programmed death 1 cell surface receptor (PD-1) and 669 in ePPND monkey studies with immune-modulators, therefore developmental toxicity is a 744 concern for biologics with these modes of action [68] . Another example involves biologics which 745 target EGFR, a receptor involved in fetal development, which is likely essential for normal 746 organogenesis, cell proliferation, and cell differentiation in the developing embryo. The mAbs 747 bevacizumab, cetuximab, panitumumab, and trastuzumab bind with the EGFR and inhibit the 748 function of the receptor, resulting in developmental toxicity [69] . Additionally, mAbs in the IgG2 749 subclass are able to cross the placenta [69] . 750 Immunogenicity is a concern with administration of biologic materials. The immunogenic 751 potential of a biologic increases with the proportion of foreign protein, and therefore humanized 752 As biologics are generally specific for their target(s) and can be quite potent, they should be 779 evaluated on a case-by-case basis. The potential for accumulation due to long half-lives, the 780 pharmacodynamic profile and the potential for developmental toxicity should be considered in 781 the hazard assessment for biologics. 782 Regarding exposure risks, exposures via the dermal, oral and inhalation routes are 783 generally expected to be low. Compounds >500 Da are not expected to be bioavailable via 784 dermal exposure [22] . Low systemic exposure potential is generally expected via the inhalation 785 route of exposure (BA<1%) in the occupational setting for biologics with a MW >10 kDa [20, 71] . historical data for known respiratory sensitizers; therefore, the structure of the biologic should be 794 examined for potential similarities to known respiratory sensitizers. 795 Occupational exposures to therapeutic proteins (like other drugs) should be kept to a 796 minimum [72] . While exposure can never be truly proven to be zero, occupational exposure 797 limits, engineering controls, administrative controls, and PPE are necessary for to protect 798 employees. Dermal exposure to drugs is never recommended and this remains the 799 recommendation for biologics. 800 801 The default BCC for mAbs, probodies and fusion proteins which are expected to exhibit 803 pharmacology at doses of ≥1 µg/kg is considered to be BCC A (≥1 µg/m 3 ), after accounting for 804 the low systemic BA following inhalation (e.g. less than 1%) for compounds with a MW >10 kDa. 805 For biologics where a pharmacological effect is expected at <1 µg/kg, BCC B is generally 806 appropriate. It is also important to take into consideration the potential for direct lung effects 807 and when the drug target is present in the lung since adverse effects would not be dependent 808 on systemic BA in this case. 809 Due to the high potency and generally low clinical doses associated with bsAbs, the 810 default BCC for bsAbs is considered to be BCC B (<1 µg/m 3 ), even after taking into account the 811 low inhalation BA and high MW. be used to evaluate payload dependent toxicity, although this toxicity is difficult to distinguish 871 from toxicity that occurs when the conjugated antibody is taken up into normal tissues [84] . 872 ADCs are designed to bind membrane-bound target proteins that can facilitate internalization 873 into tumor cells by receptor-mediated endocytosis [85] . Because of the high affinity of the initial 874 binding interaction, ADCs undergo target-mediated drug disposition (TMDD), meaning that the 875 properties of the target influence the PK of the drug [86] . Target expression, internalization, 876 turnover, accessibility and binding affinity all impact the PK of ADCs. After administration, 877 ADCs distribute to occupy target sites that are present in both normal and diseased tissue. 878 879 The health hazards of ADCs may be dissected into the relative parts or building blocks of these 881 hybrid molecules and can also be evaluated for the ADC as a whole. There are the obvious 882 hazards associated with the highly potent cytotoxic payload, hazards associated with the 883 monoclonal antibody scaffold, and hazards associated with the linker molecules, which can then 884 vary depending if the linker is bound with the payload or antibody. These agents typically induce cell death in rapidly dividing tissues and induce hematologic and 890 GI toxicity. Genotoxicity, and reproductive and developmental toxicities are also associated with 891 exposure to these highly potent cytotoxic drugs, and neurotoxicity is a known adverse effect of 892 the tubulin disruptors [88] . Radio-nucleotides were also historically used as ADC payloads, but 893 have been replaced in modern ADCs by the use of these highly potent cytotoxic drugs [75] . 894 The antibody scaffolds may have potential toxicity resulting from the intended and 895 unintended pharmacological action as well as immunogenic effects associated with exposure to 896 proteins. Proteins are thought to have lower potential to cause harm, and most of these are 897 humanized antibodies with a lower potential for off target immunological events. They are 898 designed to preferentially target cancer cells rather than normal tissues, which can lower the 899 hazard of off target pharmacology. 900 The linkers are typically small molecules with hazards that may vary and need to be 901 assessed on a case-by-case basis. Linking strategies that take advantage of the properties of 902 endogenous amino acids (such as engineered antibodies or peptides) are unlikely to be toxic on 903 their own, or to significantly contribute to the toxicity of either the antibody or the payload. The 904 toxicity of other types of linkers would need to be evaluated on a case-by-case basis. Potential 905 issues include the possibility of linking to endogenous proteins or other cellular macromolecules, 906 or altered immune responses. 907 For the ADC as a whole, it is important to note that even though the payload is 908 connected to an antibody, it does not mean that the toxicity to the payload will be reduced. 909 There is a strong possibility that the payload could be released despite not having a (tumor) 910 binding site. Therefore, it is critical to account for the hazards associated with the payload and 911 not to assume the linker to the antibody is systemically stable. 912 913 In the workplace, potential routes of exposure to the intact ADC or its respective components 915 include inhalation, ingestion (via mucocilliary transport from the lung, hand to mouth contact, 916 etc.) and dermal contact (depending on MW, etc.). The overlying concern with occupational 917 exposure to these types of molecules is the highly potent and toxic nature of the payload 918 component. A critical attribute of any ADC is the amount of drug loading, or the average ratio of 919 conjugated payload to antibody. This is referred to as the drug-to-antibody ratio (DAR). Since 920 J o u r n a l P r e -p r o o f the DAR dictates the amount of payload delivered per internalized antibody, it strongly 921 influences both efficacy and toxicity. In addition, depending on the conjugation and linker 922 technologies used, high-DAR ADCs can have poor biophysical characteristics (e.g., 923 hydrophobicity, aggregation) that reduce efficacy and increase toxicity [73] . Another important 924 factor to consider when assessing the toxicity of the ADC and individual components is the 925 relative size of the component molecules. While the payload and linker may have molar masses 926 in the several hundreds of Da, the antibody will typically have a molar mass of around 150,000 927 Da, though antibody fragments may be significantly smaller. As such, the payload element of 928 the ADC may only constitute less than 0.5% by weight of the total MW; a potentially important 929 fact when safe exposure levels are typically quoted in mass terms. Of course, with smaller 930 antibody fragment utilization, this effect will be reduced and the toxic payload will constitute a 931 greater proportion of the compound mass. 932 During each step to the manufacturing process, the hazards may change based on the 933 nature of the components being utilized in that step of the manufacturing process. The 934 relatively low toxicity of antibody proteins, and the common processing of such macromolecular 935 materials in enclosed solution or suspension forms, results in a relatively low risk of intolerable 936 exposure by main traditional routes (inhalation, ingestion and skin absorption). In addition, the 937 BA of such large biologically derived macromolecules by traditional exposure routes (ingestion 938 and airborne inhalation) is low due to instability of proteins in the GI tract as well as low 939 inhalation BA of such large molecules from the respiratory tract. The processes used for the 940 manufacture of payload and subsequent conjugation to the antibody scaffold are typical "wet 941 chemistry" covering all normal synthetic chemistry and pharmaceutical processing steps for 942 small molecules, which includes the synthesis of the payload and linker and associated 943 purification and isolation steps including chemical reaction, chromatography distillation, filtration, routes are considered. It is important to note that a payload could be released from an ADC 959 despite not having a binding site. Therefore, it is critical to protect directly for the contribution of 960 the payload and not to assume the linker to the antibody is systemically stable. The extreme 961 toxicity of the payload warrants consideration of all routes, with control of hand contamination in 962 particular being a concern as this is a major transfer route into ocular and ingestion routes of 963 exposure. The high toxicity and uncertainty of exposure uptake efficiencies means that other 964 activities that may lead to exposure to trace levels of residues, such a might occur during 965 manual cleaning of contaminated equipment may be significant, and the potential and 966 mechanisms for equipment and containers to become contaminated on exposed external 967 surfaces should also be assessed. 968 969 3.5.7. Occupational exposure banding guidance recommendation 970 Occupational exposure banding recommendations are based on the inherent hazards 971 associated with exposures to each component of the ADC manufacturing process. Therefore, 972 J o u r n a l P r e -p r o o f those components containing the intact or generally active payload, which would include the 973 payload itself and the payload plus the linker, which are all small molecules components, are 974 assigned to ECB 5 special case (< 0.1 µg/m 3 ) due to their highly potent cytotoxic hazards. The 975 intact ADC, while retaining the cytotoxic hazards, is assigned to ECB 5 (0.1 -< 1 µg/m 3 ) due to 976 its mixed biological/small molecule dilution effect. The intact antibody components are assigned 977 to Biologic Control Category A (≥ 1 µg/m 3 ). The linker molecules are typically evaluated on a 978 case-by-case basis, but generally fall within ECB 3 (10 -<100 µg/m 3 ; <1000 µg/day) or ECB 4 979 (1 -<10 µg/m 3 ; <100 µg/day). The pairing of a radioactive element with a targeted drug/compound results in a dual hazard, 1021 one from the toxicity of the compound or drug substance and one from the radioactive effects. 1022 Non-ionizing radiation is essential to life, but excessive exposures will cause tissue damage. All 1023 J o u r n a l P r e -p r o o f forms of ionizing radiation have sufficient energy to ionize atoms that may destabilize molecules 1024 within cells and lead to tissue damage [92] . The hazards attributable to the small molecule or 1025 target-oriented compound are aligned with those described herein under the appropriate 1026 modality. 1027 1028 3.6.6. Occupational hazard and exposure considerations 1029 With regards to the occupational hazard of radiation exposure, the guiding principle of radiation 1030 safety is that exposure be controlled to "as low as reasonably achievable" ("ALARA") [93] . 28%, respectively [112, 113] . 1116 Less common hazard considerations include "on-target off-tumor" toxicity resulting from 1117 target engagement of target antigen on non-pathogenic tissues [114] , anaphylaxis resulting from 1118 host recognition of infused foreign components [115] , and the risk of insertional oncogenesis as 1119 observed in gene therapy of hematopoietic stem cells for X-linked severe combined 1120 immunodeficiency and chronic granulomatous disease [116] . 1121 From an occupational perspective, common hazards include accidental punctures with 1122 needles or contaminated sharps, spills and splashes on the skin and mucus membranes, and 1123 inhalation exposure to infectious aerosols. Since workers tasked with manufacturing CAR T 1124 cells will be handling cells isolated from individual patients, the nature of the hazard will be 1125 dependent on the patients themselves (e.g., potentially infected with viruses pathogenic for 1126 humans such as HIV, adenovirus, etc.). 1127 and adaptive immune responses [125] . 1189 Clinical studies on oncolytic adenoviruses have demonstrated varied PK depending on the route 1206 of administration, adenovirus serotype and associated genetic modifications, such that 1207 generalizations regarding pharmacokinetic (PK) parameters cannot be made. For example, in a 1208 Phase 1 study of enadenotucirev (a group B Ad11p/Ad3 chimeric oncolytic adenovirus) 1209 administered intravenously to patients with epithelial solid tumors, the half-life was short (16.7 1210 minutes) and independent of dose and administration frequency [129] . Post-infusion viral 1211 shedding (i.e., release of adenovirus from injection sites and patient secretions) manifested as 1212 buccal shedding and rectal shedding (both of which were related to dose level), and to a lesser 1213 extent, urine shedding. In a second example, a Phase 1 dose escalation study examined the 1214 safety and host immune response of telomelysin (OBP-301) following a single intratumoral 1215 injection in patients with advanced solid tumors [130] . Telomelysin is a telomerase-specific 1216 replication-selective adenovirus in which the human telomerase reverse transcriptase promotor 1217 (Table 2) * Not an exhaustive list ** COVID-19 Candidate information obtained from the WHO's authoritative and continually updated list of COVID-19 vaccine candidates located at: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines (accessed 07August2020) *** Note that BCCs are utilized at BMS, however alternative banding paradigms for biologics are also used in the pharmaceutical industry which are equally effective in controlling exposures J o u r n a l P r e -p r o o f NIOSH list of antineoplastic and other hazardous drugs in healthcare settings. US 1518 Department of Health and Human Services Technical report: The NIOSH occupational exposure banding process for chemical risk 1527 management. US Department of Health and Human Services National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No Application of the threshold of 1531 toxicological concern concept to pharmaceutical manufacturing operations Structure-based 1534 thresholds of toxicological concern (TTC): guidance for application to substances present at low levels in 1535 Chem Toxicol Estimation of toxic hazard--a decision tree approach Special endpoint and product specific 1541 considerations in pharmaceutical acceptable daily exposure derivation Guideline IHT, editor Assessment and Control Of Dna Reactive (Mutagenic) Impurities In 1544 Pharmaceuticals To Limit Potential Carcinogenic RISK M7. International conference on harmonization of 1545 technical requirements for registration of pharmaceuticals for human use (ICH): Geneva Derivation of internal dose-based thresholds of toxicological concern 1547 for occupational inhalation exposure to systemically acting organic chemicals Exposure based waiving: the application of the toxicological 1550 threshold of concern (TTC) to inhalation exposure for aerosol ingredients in consumer products. Food 1551 and Chemical Toxicology Derivation of an inhalation TTC for the workplace based 1553 on DNEL values reported under REACH Derivation of occupational thresholds of toxicological concern for 1555 systemically acting noncarcinogenic organic chemicals Garrod AN, Rajan-Sithamparanadarajah R. Developing COSHH Essentials: dermal exposure, 1560 personal protective equipment and first aid Application of the threshold of toxicological concern concept when applied 1563 to pharmaceutical manufacturing operations intended for short-term clinical trials Epub 2012/06/27 Threshold of toxicological concern (TTC) 1567 for developmental and reproductive toxicity of anticancer compounds. Regulatory Toxicology and 1568 Pharmacology The toxicologist's pocket handbook Bioavailability of protein 1571 therapeutics in rats following inhalation exposure: Relevance to occupational exposure limit 1572 calculations Bioavailability of Therapeutic 1575 Proteins by Inhalation-Worker Safety Aspects The 500 Dalton rule for the skin penetration of chemical compounds and 1577 drugs Chemical and physical instabilities in manufacturing and storage of 1579 therapeutic proteins Antibiotic Discovery and Development Molecular properties that 1583 influence the oral bioavailability of drug candidates Prodrugs--from serendipity to rational design Prodrugs -Recent approvals and a glimpse of the pipeline The prodrug of 7,8-dihydroxyflavone 1591 development and therapeutic efficacy for treating Alzheimer's disease. Proceedings of the National 1592 Academy of Sciences of the United States of America Drug Excretion Philadelphia: Content Repository Only! Guideline on setting health based exposure limits for use in risk identification in the 1600 manufacture of different medicinal products in shared facilities Pharmacokinetic and 1602 toxicity profile of a phosphorothioate oligonucleotide following inhalation delivery to lung in mice FDA-approved oligonucleotide therapies in 2017 Uptake, efficacy, and 1608 systemic distribution of naked, inhaled short interfering RNA (siRNA) and locked nucleic acid (LNA) 1609 antisense Clinical expert panel on 1612 monitoring potential lung toxicity of inhaled oligonucleotides: consensus points and recommendations Specific mutations induced by triplex-forming 1616 oligonucleotides in mice OSWG 1618 Recommendations for Genotoxicity Testing of Novel Oligonucleotide-Based Therapeutics Advantageous toxicity profile of 1621 inhaled antisense oligonucleotides following chronic dosing in non-human primates Chimeric fusion proteins used for therapy: indications, mechanisms, and safety. Drug 1624 Peptide therapeutics: current status and future directions Chapter 9 -Drug Excretion Inhalation therapy with the 1631 synthetic TIP-like peptide AP318 attenuates pulmonary inflammation in a porcine sepsis model Inhaled protein/peptide-based therapies for respiratory 1635 disease Inhaled PYY(3-36) 1638 dry-powder formulation for appetite suppression Formulation design and in vivo 1641 evaluation of dry powder inhalation system of new vasoactive intestinal peptide derivative Nonclinical safety 1645 assessment of SPX-101, a novel peptide promoter of epithelial sodium channel internalization for the 1646 treatment of cystic fibrosis Managing 1649 the risk of occupational allergy in the enzyme detergent industry Bispecific antibodies in cancer immunotherapy The making of bispecific antibodies Probody therapeutics for targeting antibodies to diseased tissue Pharmacokinetics of Monoclonal Antibodies Epub 2017/06/28 Monoclonal antibodies: technologies for early 1664 discovery and engineering Tumor-specific 1667 activation of an EGFR-targeting probody enhances therapeutic index Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters Epub 2015/07/17 Antibody-cytokine fusion proteins for treatment of 1674 cancer: engineering cytokines for improved efficacy and safety Antibody-cytokine fusion proteins: Biopharmaceuticals with 1678 immunomodulatory properties for cancer therapy Monoclonal Antibodies: A 1681 Review Therapeutic monoclonal antibodies approved by FDA in 2017 Antibodies to watch Releasing the brake on the immune system: ipilimumab in melanoma 1689 and other tumors Bispecific antibodies: a mechanistic review of 1692 the pipeline Emicizumab, a bispecific antibody recognizing coagulation 1694 factors IX and X: how does it actually compare to factor VIII? Probody therapeutics: an emerging class of therapies 1696 designed to enhance on-target effects with reduced off-tumor toxicity for use in immuno-oncology Translational Aspects of Bispecific Antibodies Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory 1702 bowel disease: adding value to current practice Pharmacokinetics interactions of 1705 monoclonal antibodies A phase I 1708 trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell 1709 coreceptor CD3 Safety and 1712 immunotoxicity assessment of immunomodulatory monoclonal antibodies Assessing the risk to health care staff from long-term exposure to anticancer 1716 drugs--the case of monoclonal antibodies Delivery of an erythropoietin-Fc 1719 fusion protein by inhalation in humans through an immunoglobulin transport pathway Bioavailability of therapeutic 1722 proteins by inhalation--worker safety aspects Safe handling of monoclonal antibodies: Too 1725 large to be hazardous Recent Developments in ADC Technology: Preclinical Studies Signal Future 1728 Clinical Trends Considerations for 1731 the nonclinical safety evaluation of antibody drug conjugates for oncology Antibody-Drug Conjugates: A Review on the Epitome of Targeted 1734 Potent antibody drug conjugates for cancer therapy Antibody-drug conjugates: linking cytotoxic payloads to monoclonal 1739 antibodies Resistance to Antibody-Drug Conjugates Pharmacokinetic Considerations for Antibody-Drug 1745 Conjugates against Cancer Absorption, distribution, metabolism, and excretion considerations for the 1748 development of antibody-drug conjugates Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue 1751 kinetics in wild-type and FcRn-knockout mice Pharmacologic target-mediated drug disposition Excretion Characterization of Antibody-Drug Conjugates: An 1757 Industry White Paper Preclinical safety profile of 1760 trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with 1761 improved tolerability Implications of receptor-mediated endocytosis and 1764 intracellular trafficking dynamics in the development of antibody drug conjugates General pharmacokinetic model for drugs exhibiting target-mediated drug 1768 disposition Strategies and challenges for the next generation of 1771 antibody-drug conjugates Toxicities of anticancer drugs and its management PET tracer development--a tale of mice and men. Cancer Imaging What's new, what's reimbursed, and what's next? Epub 2018/02/14 Suggested pathway to assess radiation safety of 1781 (1)(8)F-labeled PET tracers for first-in-human studies Occupational Safety and Health Administration: Safety and Health Topics -Radiation. 1785 2020. 1786 93. Control CfD. CDC Radiation Safety United States Environmental Protection Agency: Federal Guidance for Radiation Protection Directive C. 59/Euratom of 5 December 2013 laying down basic safety standards for protection 1790 against the dangers arising from exposure to ionising radiation, and repealing Directives 1791 Use of a SCID mouse/human 1800 lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity The urgent need to recover 1804 MHC class I in cancers for effective immunotherapy Antigen-Specific T-Cell Activation Independently of the 1808 MHC IL13Ralpha2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent 1812 Design of a 1816 phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells 1817 advanced or recurrent head and neck cancer The market for chimeric antigen receptor T cell therapies Cellular kinetics of CTL019 in 1822 relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia Clinical Pharmacological Considerations on CAR-T Cell Therapy for Cancer Toxicity and management in CAR T-cell therapy Epub 2016/09/15 Current concepts in the 1833 diagnosis and management of cytokine release syndrome Kinetics and biomarkers of severe 1837 cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy Chimeric antigen receptor T-cell neuropsychiatric toxicity in acute 1841 lymphoblastic leukemia Global Registration Trial 1844 of Efficacy and Safety of CTL019 in Pediatric and Young Adult Patients with Relapsed/Refractory Clinical Lymphoma Myeloma and 1846 Leukemia Cell Therapy in Refractory Large B-Cell Lymphoma. The New England journal of 1849 medicine Case report of a 1852 serious adverse event following the administration of T cells transduced with a chimeric antigen 1853 receptor recognizing ERBB2 Insertional 1859 oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1 A guide to manufacturing CAR T cell therapies Control CfD, Prevention. Biosafety in microbiological and biomedical laboratories (BMBL) Into the clinic: Talimogene laherparepvec (T-VEC), a 1868 first-in-class intratumoral oncolytic viral therapy Adenoviruses: update on structure and function Advantages and disadvantages of multiple different methods of 1876 adenoviral vector construction Oncolytic adenoviruses as a 1882 therapeutic approach for osteosarcoma: A new hope Oncolytic viruses-immunotherapeutics on the rise Recent advances in oncolytic adenovirus therapies for cancer Epub 2016/07/06 China approves world's first oncolytic virus therapy for cancer treatment Phase III randomized clinical trial of 1892 intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based 1893 chemotherapy in treating squamous cell cancer Viral Pharmacokinetics and Host Immune Response Following Intratumoral 1900 Injection of a Conditional, Replicative, Oncolytic Adenovirus Telomelysin (OBP-301). Molecular Therapy Oncolytic Adenoviruses in Patient Autopsy Samples Reveals Vascular Transduction of Noninjected 1904 Tumors and Tissues Homologous 1911 recombination in E3 genes of human adenovirus species D Sibbald B. Death but one unintended consequence of gene-therapy trial A practical guide to the 1918 handling and administration of personalized transcriptionally attenuated oncolytic adenoviruses 1919 (PTAVs) A phase I study of a 1924 tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases Phase I study of adenovirus p53 1929 administered by bronchoalveolar lavage in patients with bronchioloalveolar cell lung Multiple hepatic arterial injections of recombinant adenovirus 1933 p53 and 5-fluorouracil after transcatheter arterial chemoembolization for unresectable hepatocellular 1934 carcinoma: a pilot phase II trial Evaluation of exposure and 1937 health care worker response to nebulized administration of tgAAVCF to patients with cystic fibrosis Epub 2015/06/13 Intervening in disease through genetically-modified bacteria Engineering the perfect (bacterial) cancer therapy Regulatory Considerations for Development of 1948 Transmission of the gut microbiota: spreading of 1951 health Classification of vaccines Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant 1959 vaccine (Gardasil®) Biothrax package insert The COVID-19 vaccine 1962 development landscape Biosafety of DNA vaccines: New generation of 1964 DNA vectors and current knowledge on the fate of plasmids after injection Seasonal influenza vaccines. Vaccines for Pandemic Influenza From lethal virus to life-saving vaccine: developing inactivated vaccines 1969 for pandemic influenza DNA vaccines against influenza viruses. Vaccines for Pandemic Influenza Vaccines for pandemic influenza: summary of recent clinical trials. 1973 Vaccines for Pandemic Influenza Safety and 1975 immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated 1976 healthy adults: a phase 1, double-blind, randomised controlled trial. The Lancet Infectious diseases WHO biosafety risk assessment and guidelines for the production and quality 1979 control of human influenza pandemic vaccines Live attenuated vaccines for pandemic influenza. Vaccines for Pandemic study indicated that despite intratumoral dosing, viral DNA was detected in 5 of 9 patient plasma 1219 samples, as early as 30 minutes and as late as 14 days post-treatment. Viral DNA was also 1220 detected in the sputum of one patient, indicating systemic dissemination following intratumoral 1221 injection [130] . Systemic dissemination of oncolytic adenoviral DNA via vascular transduction 1222 has also been demonstrated in a study examining post-mortem tissues of cancer patients 1223 treated with this modality either intratumorally or intravenously, and whose deaths were caused 1224 by disease progression rather than the treatment vector [131] . Oncolytic adenoviral DNA was 1225 recovered in a wide array of tissues, including both injected and non-injected tumors and 1226 various normal tissues, including the brain. 1227 1228 Generally, the use of oncolytic adenoviruses appears to be reasonably safe following local 1230 administration (i.e., intratumoral) and lower systemic doses, although the development of newer 1231 generations of adenoviruses expressing transgenes and possessing altered capsids or different 1232 promoters could alter the safety profile [132] . Viral shedding of engineered adenovirus vectors 1233 could theoretically result in homologous recombination between wildtype adenoviruses of the 1234 same subgroup, leading to new wildtype adenoviruses that possess transgenes or have 1235 expanded tissue tropism due to retargeting strategies [132, 133] . To date, no such 1236 recombination events have been observed in clinical trials. 1237 1238 Given the mechanism of action of oncolytic adenoviruses, one might consider CRS an outcome 1239 of concern. However, in the thousands of patients that have received adenoviruses 1240 therapeutically, only one patient (who consequently, had an underlying metabolic disorder) has 1241 died as a result of CRS [134] . Based on this prior extensive clinical experience, the risk of 1242 severe CRS and toxicity is generally deemed to be minimal, especially considering the 1243 J o u r n a l P r e -p r o o f neoantigens expressed by the virus are not typically present in normal tissue and therefore, 1244 cross-reactive T-cell responses are unlikely to occur [135] . 1245 1246 3.8.6. Occupational hazard and exposure considerations 1247Occupational exposure to an adenovirus is generally through the upper respiratory tract via 1248 aerosol exposure, although other potential routes of exposure include via mucus membranes 1249 (splash of virus to eye, nose, mouth), parenteral (needle stick or sharp object injury) and contact 1250 with non-intact skin [135] . In general, adenovirus infection most commonly causes respiratory 1251 illness, although, depending on the infecting serotype, they may cause other illnesses such as 1252 gastroenteritis, conjunctivitis, cystitis, and rash [136] . Adenovirus infection of the respiratory 1253 systems typically can present as a spectrum of ailments ranging from the common cold 1254 syndrome to pneumonia, croup, and bronchitis. In terms of exposure scenarios specifically, 1255 special consideration must be given to the potential for viral shedding and human-to-human 1256 transmission. In the clinical setting, viral shedding can occur from injection sites and patient 1257 excretions, and prevalence has been demonstrated to increase with higher doses and systemic 1258 administration [137] [138] [139] . Preclinically, viral shedding could result in exposure via contact with 1259 animal secreta, excreta and bedding. 1260Pregnant individuals and those who are severely immunocompromised are particularly 1261 susceptible to adenovirus exposure and should exercise extreme caution when handling 1262 adenoviruses, as infection could lead to systemic disease (e.g. hepatitis). There is a paucity of 1263 data in terms of occupational exposures to oncolytic adenoviruses. However, a study in which 1264 health-care workers involved in the aerosolized administration of adeno-associated virus (AAV) 1265 during a Phase II cystic fibrosis study determined that individuals were exposed to an estimated 1266 0.0006% of the administered doses based on airborne vector particle concentration. At this level 1267 of exposure, the prevalence of symptoms (typically associated with adenovirus exposure) was 1268 very low, the spectrum of symptoms was similar in both active and control health care workers, 1269 J o u r n a l P r e -p r o o f and there were no reported negative health effects [140] . It is assumed that oncolytic 1270 adenoviruses and AAVs would behave similarly in this exposure scenario. Therefore, if proper 1271 handling precautions and engineering controls are implemented as described in the proceeding 1272 section, occupational exposure is expected to be limited. The main health hazards associated with GM bacteria are the risk of infection and the risk of 1332 transient or stable transfer of identified genes of concern (e.g. antibiotic resistance genes) in the 1333 LBP to another species present in host sites exposed to product colonization. The ideal vaccine elicits the exact immune response that occurs during natural infection, safely 1364 inducing a strong humoral and cellular immune response. Vaccines work by mimicking disease 1365 agents and stimulating the immune system to build up defenses against them. Vaccines are 1366 generally created to express one or more antigens present on a pathogen to prime an 1367 individual's immune system, so that if the individual is exposed to the pathogen in the future, the 1368 immune system will respond swiftly with a specific defense. Briefly, antigen-presenting cells 1369 (APCs; e.g., dendritic cells, macrophages) take up and process the pathogen-specific antigen(s) 1370and present them to CD4+ T cells via the MHC class II pathway and then to B cells, ultimately 1371 resulting in the production of antibodies. For most infectious diseases, primary protection is 1372 mediated by existing antibodies, whereas for intracellular pathogens (e.g. mycobacterium 1373 J o u r n a l P r e -p r o o f tuberculosis), protection is mediated by MHC class I-restricted CD8 T cell responses. The goal 1374 of vaccination is to produce a memory of the vaccine antigen, so that if an individual is exposed 1375 to the pathogen in the future, the memory cells will recognize it and the immune system will be 1376 able to respond more effectively than if it had never encountered the pathogen. 1377 (L1) protein of HPV Types 6, 11, 16, and 18 and is administered with Alum adjuvant [149] . Table 5 . 1390Coronavirus disease or COVID-19 vaccine candidates exist for each of the vaccine platforms 1391 and several of these are noted [151] . The WHO's authoritative and continually updated list of 1392 COVID-19 vaccine candidates is located at: https://www.who.int/publications/m/item/draft-1393 landscape-of-covid-19-candidate-vaccines. and revert to pathogenic forms are of concern. For example, whole virus vaccines are 1412 considered too reactive, particularly in young children [154] . In the case of plasmid DNA, there 1413 is a concern that the DNA vaccine could possibly integrate into host genomes, increasing the Inhalation exposure to live viruses or bacteria are of concern. Upon inhalation, live 1437 attenuated viruses have the potential to replicate in the mucosa of the respiratory tract [159] . 1438Human-to-human transmission is expected to be unlikely since replication is attenuated and the 1439 virus titers would be below those considered necessary for human infection [158] . Potential 1440 adverse effects may be at worst, similar to those observed upon intranasal administration of live 1441 attenuated influenza, which consist of some effects of local viral replication (e.g., nasal 1442 congestion). With the exception of surrogate viruses, the use of wild type pandemic-like viruses 1443 to develop pandemic vaccine strains presents considerable biosafety risks to personnel in 1444 vaccine development and manufacturing facilities [158] . Additionally, viruses may be expected 1445 to survive for at least a short time (hours) on surfaces and thus provide a potential means of 1446 infection for workers [158] . Therefore, the wild-type pandemic-like viruses present the greatest 1447 occupational health concern. 1448 1449 3.10.7. Occupational exposure banding guidance recommendation 1450 J o u r n a l P r e -p r o o f Vaccine production facilities are designed to maintain the sterility of the product. Therefore, 1451although there is opportunity to be exposed to the virus and/or antigens, occupational 1452 exposures are expected to be limited. The WHO biosafety risk assessment and guidelines for 1453 the production and quality control of human influenza pandemic vaccines presents guidance to 1454 vaccine manufacturers on the safe production of influenza vaccines [158] . According to the 1455 WHO guideline, all laboratory procedures involving live highly pathogenic influenza viruses 1456should take place at a high level of biological containment (e.g., BSL3 and above, as 1457 recommended by WHO and national regulatory bodies). Stringent vaccine biosafety control 1458 measures with specific enhancements, defined as BSL2 enhanced (BSL2-e; pandemic 1459 influenza vaccine) and BSL3 enhanced (BSL3-e; pandemic influenza vaccine) are designed to 1460 manage the risk from vaccine production and quality control using such viruses during the pre-1461 pandemic or inter-pandemic period [158] . In the United Kingdom, it is necessary to use BSL4 1462 facilities, but in other parts of the world (e.g. United States) working with highly pathogenic avian 1463 influenza (HPAI) viruses is acceptable under BSL3-e [154] . Note that while this guidance exists, 1464 a risk assessment should be performed that will depend on the nature of the strain and the Use of this decision tree, and the potencies included herein, should be considered as a rough 1496 guide for initial band selection. Ultimate selection of the band should come from a qualified 1497 occupational toxicologist, and rely on the consideration of a number of additional criteria such as 1498 the innate hazard of the therapeutic, its pharmacokinetics, and pharmacodynamics, among 1499 others. For example, an additional safety factor may need to be applied for compounds which 1500 are mutagenic or teratogenic, resulting in a more restrictive band. 1501 J o u r n a l P r e -p r o o f a ADC banding is generally driven by the warhead potency; b Follow guidance for radiolabeled 1502 compounds, banding is based on the API; c Biologic materials made through biological 1503 processes (i.e. cell culture); d This biologically significant effect should also be clinically relevant; 1504 e Note that for live viruses, enhanced control measures may be required. Abbreviations: aa = 1505 amino acids; sc = special case.